The FDA has approved the first immuno-oncology combination therapy for patients with advanced renal cell carcinoma.
Browsing: renal cell cancer
Recently at the 2018 ASCO-SIC Clinical immune-oncology symposium (CA, USA, 25-27 January) a panel discussed…
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape
This prospective, noninterventional study evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab.
What advances have been made in immune therapy for renal cell carcinoma? Discover what the experts say in this opinion article from Future Oncology.
Sociodemographic disparities in treatment and survival of small localized renal cell carcinoma: surgical resection versus thermal ablation
This research article investigates practice trends in the use of surgical resection versus thermal ablation for the management of early stage renal cell carcinoma with regard to sociodemographic factors and associated outcome.
A review of the some of the most recent available data for immune checkpoint inhibitors for patients with renal cell carcinoma.
Retrospective analysis finds association between increased expression of metabolism-associated genes and lack of response to nivolumab in PD-L1- positive renal cell carcinoma.
Read more about the potential of two classes of checkpoint inhibitors – anti-CTLA-4 and anti-PD1/PD-L1 agents – both currently under investigation in bladder and renal cell cancer.
A novel combination of a tyrosine kinase inhibitor and a MEK inhibitor has been demonstrated to impede the growth of kidney cancer in preclinical studies.
Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions
This review examines the current treatment algorithm for the management of patients with poor-risk mRCC, and considers available and future therapies for this patient subgroup, as well as emerging concepts and outstanding questions in the management of this disease.